The Israeli drug giant has announced former Bristol-Myers Squibb co-Executive Director Jeremy Levin will assume the reins as Teva’s new CEO. The choice of Levin underscores Teva’s interest to move beyond generics and acquire companies developing novel treatments. At BMS, Levin spearheaded no less than 17 highly successful strategic acquisitions in the past few years. Both Teva and BMS have shown interest in orphan diseases including ALS, which makes Levin’s next moves worth watching closely.
Click here to read more.Share this: